This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q3.
Tariff Woes Haunt Wall Street: Take Refuge in These 5 Stocks
by Tirthankar Chakraborty
Companies involved in artificial intelligence, e-commerce, biotechnology and gaming businesses are immune to trade conflicts. They are part of an evolving trend that provides stability during tough times and their quest for the next big thing fuels growth.
Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Illumina (ILMN)
by Madeleine Johnson
Invest in the medical space with this DNA sequencing-focused company.
Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates
by Zacks Equity Research
Lower peritoneal dialysis sales in Q2 hurt Fresenius Medical (FMS); solid geographical performance encourages.
Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Solid performance in the Global Industrial and Global Institutional segments boost Ecolab's (ECL) top line in Q2.
Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.
athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View
by Zacks Equity Research
An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.
Sprint (S) Gears Up for Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Sprint (S) is likely to report lower revenues in first-quarter fiscal 2018 on a year-over-year basis due to weak demand patterns in the industry.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
Abiomed (ABMD) Lags Q1 Earnings Estimates, Raises '19 View
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella line continues to drive growth in Q1. A strong guidance instills investors' optimism.
Why Earnings Season Could Be Great for Illumina (ILMN)
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
by Zacks Equity Research
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group
Integra (IART) Reports In-Line Q2 Earnings, Tapers View
by Zacks Equity Research
Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.
Varian Medical (VAR) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Varian Medical (VAR) see strong growth in Oncology Systems. Solid guidance boosts investors' optimism.
AbbVie Secures FDA Approval for Endometriosis Drug Elagolix
by Zacks Equity Research
AbbVie (ABBV) gains an FDA approval for its late-stage pipeline candidate, Orilissa, for the treatment of moderate to severe pain associated with endometriosis in women.
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
by Zacks Equity Research
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
What's in the Cards for CVS Health (CVS) in Q2 Earnings?
by Zacks Equity Research
CVS Health (CVS) is optimistic about living up to its strong earnings surprise history year over year in Q2 as well, courtesy of gains from the Pharmacy Services segment.
LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.